Alexion Pharmaceuticals (ALXN)
In a report released today, Raju Prasad from William Blair maintained a Hold rating on Alexion Pharmaceuticals. The company’s shares closed last Thursday at $155.92, close to its 52-week high of $162.60.
According to TipRanks.com, Prasad is a 5-star analyst with an average return of 28.7% and a 62.4% success rate. Prasad covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Crispr Therapeutics AG, and Rocket Pharmaceuticals.
The word on The Street in general, suggests a Hold analyst consensus rating for Alexion Pharmaceuticals with a $175.80 average price target, representing a 13.2% upside. In a report released today, Piper Sandler also downgraded the stock to Hold with a $166.00 price target.
Replimune Group (REPL)
In a report released today, Jonathan Chang from Leerink Partners maintained a Buy rating on Replimune Group, with a price target of $56.00. The company’s shares closed last Thursday at $40.76.
According to TipRanks.com, Chang is a 5-star analyst with an average return of 36.4% and a 58.2% success rate. Chang covers the Healthcare sector, focusing on stocks such as Adaptimmune Therapeutics, Karyopharm Therapeutics, and Mersana Therapeutics.
Replimune Group has an analyst consensus of Strong Buy, with a price target consensus of $57.75.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.